The association of the metabolic syndrome with target organ damage : focus on the heart, brain, and central arteries
(2020) In Expert Review of Cardiovascular Therapy 18(9). p.601-614- Abstract
Introduction: The metabolic syndrome (MetS) is an adverse metabolic state composed of obesity, hyperglycemia/pre-diabetes, hypertension, and dyslipidemia. It substantially increases the risk of type 2 diabetes, cardiovascular disease (CVD) and mortality, and has a huge impact on public health. Area covered: The present review gives an update on the definition and prevalence of MetS, and its impact on cardiac structure and function as well as on the brain and central arteries. The association with CVD and mortality risk is discussed. Focus is mainly directed toward the subclinical target organ damage related to MetS. Data is also critically reviewed to provide evidence on the incremental prognostic value of overall MetS over its... (More)
Introduction: The metabolic syndrome (MetS) is an adverse metabolic state composed of obesity, hyperglycemia/pre-diabetes, hypertension, and dyslipidemia. It substantially increases the risk of type 2 diabetes, cardiovascular disease (CVD) and mortality, and has a huge impact on public health. Area covered: The present review gives an update on the definition and prevalence of MetS, and its impact on cardiac structure and function as well as on the brain and central arteries. The association with CVD and mortality risk is discussed. Focus is mainly directed toward the subclinical target organ damage related to MetS. Data is also critically reviewed to provide evidence on the incremental prognostic value of overall MetS over its individual components. Expert commentary: MetS is a clinical risk condition associated with subclinical and clinical CVD and mortality. Roughly, 30% of the world population suffer from MetS. As all components of the MetS are modifiable, optimal preventive and therapeutic measures should be initiated to improve CV risk control, particularly aggressively treating hypertension and hyperglycemia, and encouraging people to adopt healthy lifestyle as early as possible is of great importance.
(Less)
- author
- Saeed, Sahrai ; Waje-Andreassen, Ulrike and Nilsson, Peter M. LU
- organization
- publishing date
- 2020-08-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cardiovascular disease, diabetes mellitus, dyslipidemia, hypertension, metabolic syndrome, mortality, obesity
- in
- Expert Review of Cardiovascular Therapy
- volume
- 18
- issue
- 9
- pages
- 14 pages
- publisher
- Future Drugs Ltd
- external identifiers
-
- pmid:32757786
- scopus:85089444641
- ISSN
- 1477-9072
- DOI
- 10.1080/14779072.2020.1807327
- language
- English
- LU publication?
- yes
- id
- 98ea328b-b2a9-4b20-aeae-2aab24148901
- date added to LUP
- 2020-08-24 13:28:39
- date last changed
- 2024-05-15 17:00:23
@article{98ea328b-b2a9-4b20-aeae-2aab24148901,
abstract = {{<p>Introduction: The metabolic syndrome (MetS) is an adverse metabolic state composed of obesity, hyperglycemia/pre-diabetes, hypertension, and dyslipidemia. It substantially increases the risk of type 2 diabetes, cardiovascular disease (CVD) and mortality, and has a huge impact on public health. Area covered: The present review gives an update on the definition and prevalence of MetS, and its impact on cardiac structure and function as well as on the brain and central arteries. The association with CVD and mortality risk is discussed. Focus is mainly directed toward the subclinical target organ damage related to MetS. Data is also critically reviewed to provide evidence on the incremental prognostic value of overall MetS over its individual components. Expert commentary: MetS is a clinical risk condition associated with subclinical and clinical CVD and mortality. Roughly, 30% of the world population suffer from MetS. As all components of the MetS are modifiable, optimal preventive and therapeutic measures should be initiated to improve CV risk control, particularly aggressively treating hypertension and hyperglycemia, and encouraging people to adopt healthy lifestyle as early as possible is of great importance.</p>}},
author = {{Saeed, Sahrai and Waje-Andreassen, Ulrike and Nilsson, Peter M.}},
issn = {{1477-9072}},
keywords = {{Cardiovascular disease; diabetes mellitus; dyslipidemia; hypertension; metabolic syndrome; mortality; obesity}},
language = {{eng}},
month = {{08}},
number = {{9}},
pages = {{601--614}},
publisher = {{Future Drugs Ltd}},
series = {{Expert Review of Cardiovascular Therapy}},
title = {{The association of the metabolic syndrome with target organ damage : focus on the heart, brain, and central arteries}},
url = {{http://dx.doi.org/10.1080/14779072.2020.1807327}},
doi = {{10.1080/14779072.2020.1807327}},
volume = {{18}},
year = {{2020}},
}